The Efficacy and Safety of Apatinib Treatment for Patients with Unresectable or Relapsed Liver Cancer: a retrospective study
Zhen Liu, Chen Jiali, Fang Yong, Xufeng Han, Pan Hongming, Han Weidong · Journal of Cancer · 2018
Not cached yet. This record was fetched live for this request and is stored after the lookup. Reopening the page should serve the cached copy.
Journal of Cancer · Ivyspring International Publisher · article · 2018
Abstract
Purpose: Liver cancer is insensitive to chemotherapy.Sorafenib is currently the standard treatment for patients with advanced diseases, with mild survival extension and several intolerable drug-related side effects.The establishment of new treatments is an unmet clinical need.The aim of our study was to assess the efficacy and safety of apatinib, a novel antiangiogenic drug, in the treatment of patients with liver cancer.Materials and Methods: Patients with unresectable or relapsed liver cancer were included in a single center, retrospective, observational study and treated with apatinib until progressive disease or unacceptable toxicity.Results: 32 patients were reviewed from January 2015 to March 2017.No complete response (CR) occurred, 5 patients (16%) showed partial response (PR), 14 patients (44%) had stable disease (SD), 13 patients (41%) had progressive disease (PD), with disease control rate of 60%.Median progression-free survival (PFS) was 5 months (95% confidence interval [CI]: 4.3-6.1 months) for hepatocellular carcinoma (HCC) and 3 months (95% CI: 2.5-4.2months) for intrahepatic cholangiocarcinoma (ICC).The median overall survival (OS) was 13 months (95% CI: 12.4-14.1 months) for HCC and 5 months (95% CI: 4.5-6.2months) for ICC, respectively.The most common adverse effects (AEs) were proteinuria (31%), secondary hypertension (28%) and liver dysfunction (13%).Conclusion: Apatinib treatment was an effective for patients with liver cancer.The toxicities were mild and tolerable.
Open the resolved locator · 10.7150/jca.26376
Metadata licence: OpenAlex metadata (CC0)